The results of the KEYNOTE-042 China extension study were crucial for the approval of pembrolizumab monotherapy as a first-line treatment of advanced PD-L1-positive NSCLC in China (36, 56). The gene discussed is CD274; the disease is non-small cell lung carcinoma.